Brokers bullish on SBI, Dr Reddy, Nestle, BOB

Published on Tue, Oct 31, 2006 at 09:21 |  Source : Moneycontrol.com

Updated at Tue, Oct 31, 2006 at 09:23  

27057 Investors following Dr Reddys Labs. Share this News with them.
0
0
Share on Tumblr

UTI Securities kas kept outperformer rating on Corporation Bank; with a target of Rs 444

ICICI Securities has maintained buy rating on SBI  and Dr Reddy

ICICI Securities has maintained buy rating on Nestle and BOB

DSP Merrill Lynch has kept buy rating on Patni Comp; with a target of Rs 470

DSP Merrill Lynch has kept neutral rating on Himatsingka Seide

DSP Merrill Lynch has kept buy rating on Divis Lab; with a target of Rs 2,970

DSP Merrill Lynch has kept buy rating on HPCL; with a target of Rs 372

India Infoline has kept buy rating on Bharti Airtel; with a target of Rs 600

India Infoline has maintained buy rating on MTNL; with a target of Rs 193

India Infoline has kept underperformer rating on HPCL

House

Stocks

Views

UTI Securities

Corporation Bank

Outperformer; with a target of Rs 444

ICICI Securities

SBI, Dr Reddy, Nestle and BOB

Buy

DSP Merrill Lynch

Patni Comp

 

 

Himatsingka Seide

 

Divis Lab

 

 

HPCL

Buy; with a target of Rs 470

 

Neutral

 

Buy; with a target of Rs 2,970

 

Buy; with a target of Rs 372

India Infoline

Bharti Airtel

 

 

MTNL

 

 

HPCL

Buy; with a target of Rs 600

 

Buy; with a target of Rs 193

 

Underperformer


  

More on Moneycontrol

Trending News

Business News

Iran's blocking internet access
Rupee rally may stall with fall against US dollar, euro "Rupee rally may stall with fall against US dollar, euro"

Sources Say Attorney General To Decide On Filing A Review Plea

The latest earning numbers FIRST on CNBC-TV18
Videos

Feb 10 2012, 21:39

Tulsian buys steel stocks; negative on sugar, ADAG

- in MARKET OUTLOOK

Feb 10 2012, 21:39

Truck demand sluggish; margins down 80bps: Shriram Trans

- in Results Boardroom

Interviews

Feb 11 2012, 11:52 | Source: CNBC-TV18

TCS to expand centers in N.America; CY12 focus on Japan  

Feb 10 2012, 15:43 | Source: CNBC-TV18

Growth in margins sustainable going forward: Shasun Pharma  

Subscribe to

Moneycontrol Newsletters

Moneycontrol.com offers you a choice of various sectoral and other newsletters for FREE!

Follow moneycontrol.com